UBS/CALL/YPSOMED N/450.001/0.01/20.12.24 Share Price

Warrant

YPSBIU

CH1322514766

Market Closed - Bid/Ask 08:50:00 02/05/2024 pm IST After market 08:45:00 pm
0.05 CHF -16.67% Intraday chart for UBS/CALL/YPSOMED N/450.001/0.01/20.12.24 0.04 -20.00%
Current month-16.67%
1 month-44.44%

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying YPSOMED HOLDING AG
Issuer UBS
YPSBIU
ISINCH1322514766
Date issued 12/02/2024
Strike 450 CHF
Maturity 20/12/2024 (213 Days)
Parity 100 : 1
Emission price 0.05 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 0.14 CHF
Lowest since issue 0.05 CHF
Spread 0.02 CHF
Spread %40.00%

Company Profile

Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Sector
-
More about the company

Ratings for Ypsomed Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Ypsomed Holding AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
328.5 CHF
Average target price
351.3 CHF
Spread / Average Target
+6.95%
Consensus
  1. Stock Market
  2. Warrants
  3. YPSBIU Warrant
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW